Pfizer Inc. $PFE Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 37.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 199,634 shares of the biopharmaceutical company’s stock after selling 120,272 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Pfizer were worth $5,087,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Cardinal Point Capital Management ULC grew its stake in shares of Pfizer by 0.7% in the 3rd quarter. Cardinal Point Capital Management ULC now owns 314,272 shares of the biopharmaceutical company’s stock worth $8,008,000 after purchasing an additional 2,240 shares during the last quarter. Slagle Financial LLC boosted its holdings in Pfizer by 3.1% during the third quarter. Slagle Financial LLC now owns 80,289 shares of the biopharmaceutical company’s stock worth $2,046,000 after buying an additional 2,450 shares in the last quarter. Lantz Financial LLC grew its position in Pfizer by 28.5% in the third quarter. Lantz Financial LLC now owns 45,324 shares of the biopharmaceutical company’s stock worth $1,155,000 after buying an additional 10,042 shares during the last quarter. Canvas Wealth Advisors LLC bought a new position in shares of Pfizer in the third quarter valued at $271,000. Finally, German American Bancorp Inc. lifted its position in shares of Pfizer by 4.6% during the 3rd quarter. German American Bancorp Inc. now owns 136,112 shares of the biopharmaceutical company’s stock valued at $3,468,000 after acquiring an additional 6,021 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PFE. Scotiabank initiated coverage on Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price on the stock. Morgan Stanley dropped their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. The Goldman Sachs Group restated a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a report on Wednesday, November 5th. UBS Group initiated coverage on shares of Pfizer in a research report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 target price on the stock. Finally, BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer has an average rating of “Hold” and an average target price of $28.06.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA grants priority review for HYMPAVZI (marstacimab) sBLA — a near-term regulatory catalyst that could speed approval and future revenue potential if approved. Pfizer Inc. (PFE) announces FDA’s grant of priority review for HYMPAVZI® (marstacimab) sBLA
• Positive Sentiment: Pfizer to collect $29M from an SEC settlement tied to the 2013 SAC Capital matter — a small but tidy legal recovery that removes uncertainty and adds cash. Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund
• Positive Sentiment: Pfizer India reports strong Q3FY26 results (profit +11%, revenue +20%), signaling healthy regional execution and bolstering sentiment among EM investors. Pfizer shares gain 9% after Q3FY26 profit up 11%, revenue grows 20%
• Neutral Sentiment: Analyst takeaways from the Q4 call: Pfizer beat EPS and revenue estimates but reported weak COVID-related sales and provided cautious 2026 commentary — investors are parsing how much the pipeline and partnerships can offset near-term headwinds. 5 Revealing Analyst Questions From Pfizer’s Q4 Earnings Call
• Neutral Sentiment: Pfizer is a trending / widely watched stock; commentary focuses on income appeal (high yield) vs. growth uncertainty — useful for income investors but not a decisive growth thesis. Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: Analysis flags that pipeline progress and partnerships are being judged against a depressed valuation — investors remain skeptical about whether collaboration deals and late-stage assets will justify current multiples. Pfizer Pipeline Progress And Partnerships Tested Against Depressed Valuation
• Negative Sentiment: Independent analyst coverage warns of an approaching patent cliff and the need for a standout obesity franchise — risks that could pressure long-term growth absent clear pipeline wins. Pfizer: ‘Hold’ As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity

Pfizer Price Performance

Shares of PFE opened at $27.61 on Wednesday. The business’s 50-day moving average is $25.70 and its 200-day moving average is $25.13. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The company has a market capitalization of $156.98 billion, a price-to-earnings ratio of 20.30 and a beta of 0.47. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.73.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The company’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.63 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.2%. Pfizer’s payout ratio is 126.47%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.